We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 8.70
Ask: 9.50
Change: -0.15 (-1.62%)
Spread: 0.80 (9.195%)
Open: 9.25
High: 9.25
Low: 9.10
Prev. Close: 9.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Apr 2018 12:43

RNS Number : 8024L
Scancell Holdings Plc
23 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

SCANCELL HOLDINGS PLC

 

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Hygea vct plc

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

18 April 2018

6. Date on which issuer notified (DD/MM/YYYY):

20 April 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.5%

0%

3.5%

374,469,098

Position of previous notification (if

applicable)

4.2%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

13,149,730

 

3.5%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Hygea vct plc

3.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

London, England

Date of completion

18 April 2018

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFVLSDIVFIT
Date   Source Headline
29th Jun 20164:35 pmRNSPrice Monitoring Extension
17th Jun 20167:00 amRNSSCIB1 Drug Product Supply
2nd Jun 20167:00 amRNSDevelopment of ImmunoBody® Vaccine
18th May 20167:00 amRNSOpens US Headquarters in San Diego
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
11th Apr 20164:11 pmRNSHolding(s) in Company
6th Apr 20167:00 amRNSHolding(s) in Company
4th Apr 201610:17 amRNSResult of the open offer
1st Apr 20167:00 amRNSResult of open offer
23rd Mar 20167:00 amRNSWorld Cancer Vaccine Congress
11th Mar 20167:00 amRNSPosting of Circular
11th Mar 20167:00 amRNSStrategic collaboration with Karolinska Institutet
9th Mar 20162:07 pmRNSPlacing and Open Offer Close
9th Mar 20167:00 amRNSProposed Placing and Open Offer
23rd Feb 20167:00 amRNSPresenting at the Biotech Capital Conference
27th Jan 20169:00 amRNSAmendment to Options
27th Jan 20167:00 amRNSHalf Yearly Report
11th Jan 20167:00 amRNSSCIB1 Early Immune Effect Observed by ImmunTraCkeR
7th Jan 20167:00 amRNSDirectorate Change
5th Jan 20167:00 amRNSKey Moditope paper published in Cancer Research
18th Dec 20157:00 amRNSUS Phase II combination study with SCIB1
20th Oct 20151:05 pmRNSResults of AGM
20th Oct 20157:00 amRNSAGM Business Update
14th Oct 20157:00 amRNSDirectorate Change
6th Oct 20157:00 amRNSSix scientific presentations at PIVAC Conference
18th Sep 20157:00 amRNSFinal Results for the year ended 30 April 2015
16th Sep 20157:00 amRNSImmunoBody presented at Cancer Vaccines Conference
27th Aug 20154:42 pmRNSNotice of AGM
30th Jul 20157:00 amRNSCollaboration with ImmunID
9th Jul 20157:00 amRNSPatient recruitment completed for SCIB1 trial
2nd Jun 20157:00 amRNSSCIB1 data update in resected melanoma patients
17th Apr 20159:00 amRNSPoster on Moditope to be presented at AACR
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20157:00 amRNSSCIB2 synergy with checkpoint inhibitor blockade
12th Jan 20157:00 amRNSPositive SCIB1 Phase 1/2 clinical trial update
15th Dec 20145:22 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSHalf Yearly Report
22nd Oct 20143:07 pmRNSChange of Registered Office
14th Oct 20146:19 pmRNSResult of AGM
14th Oct 20147:00 amRNSAppointment of Nominated Adviser and Broker
14th Oct 20147:00 amRNSAGM research and development update
30th Sep 20147:00 amRNSPresent at the 14th Annual Biotech in Europe Forum
19th Sep 20149:57 amRNSNotice of AGM
12th Sep 20147:00 amRNSPresenting at Upcoming Scientific Conferences
4th Sep 20147:00 amRNSFinal Results
12th Aug 20147:00 amRNSSynergy of SCIB1 with checkpoint inhibitors
19th Jun 20147:00 amRNSDirector/PDMR Shareholding
6th Jun 20147:00 amRNSDNA ImmunoBody Patent Granted in United States
2nd Jun 20147:00 amRNSUpdate on Phase 1/2 trial of SCIB1 in melanoma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.